Abstract
Background
Atrialfibrillation (AF) is associated with the activation of the renin‐angiotensin‐aldosterone system in the atria. It is not clear whether the expression of a mineralocorticoid receptor (MR), or 11β‐hydroxysteroid dehydrogenase type 2 (11βHSD2), conferring aldosterone specificity to the MR, in patients with AF is altered.
Hypothesis
Patients with AF may be associated with increased expression of MR and 11βHSD2 in the atria.
Methods
Atrial tissue samples of 25 patients with rheumatic heart valve disease undergoing a valve replacement operation were examined. A total of 13 patients had chronic persistent AF (>6 mo) and 12 patients had no history of AF. The MR and 11βHSD2 expression were analyzed at the mRNA and protein level. The localization of MR and 11βHSD2 in atrial tissue was performed using specific immunohistochemistry staining.
Results
The results of real‐time quantitative polymerase chain reaction (PCR) showed that AF groups, in comparison with sinus rhythm, had a higher mRNA expression level of MR or 11βHSD2 (all P < 0.01). Both the MR and 11βHSD2 protein expression level in atrial tissue were also significantly increased in patients with AF compared with patients with sinus rhythm (P < 0.05 or P < 0.01). The immunohistochemical staining of MR or 11βHSD2 demonstrated that MR and 11βHSD2 predominately located in the cytoplasm of myocardial cells in the atrium and the intensity and density of immunostaining appeared to be increased in the atria of patients with AF compared to those without AF.
Conclusions
Increasing expression of MR and 11βHSD2 in the atria during AF is one of the molecular mechanisms for development of atrial interstitial fibrosis in patients with AF. These findings may have an important impact on the treatment of AF with aldosterone antagonists. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (1.1 MB).
References
- 1. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long‐lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331–336. [DOI] [PubMed] [Google Scholar]
- 2. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long‐standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090–2098. [DOI] [PubMed] [Google Scholar]
- 3. Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88: 906–909.11676961 [Google Scholar]
- 4. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–1248. [DOI] [PubMed] [Google Scholar]
- 5. Yoshida M, Ma J, Tomita T, et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 2005; 11: 12–16. [DOI] [PubMed] [Google Scholar]
- 6. Pitt B, Zannad F, Remme WJ, et al. The effects of spironolactone on morbidity and mortality in patients with serve heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717. [DOI] [PubMed] [Google Scholar]
- 7. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321. [DOI] [PubMed] [Google Scholar]
- 8. Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000; 57: 1364–1369. [DOI] [PubMed] [Google Scholar]
- 9. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583–585. [DOI] [PubMed] [Google Scholar]
- 10. Draper N, Stewart PM. 11β‐hydroxysteroid dehydrogenase and the pre‐receptor regulation of corticosteroid hormone action. J Endocrinol 2005; 186: 251–271. [DOI] [PubMed] [Google Scholar]
- 11. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone‐driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69–76. [DOI] [PubMed] [Google Scholar]
- 12. Spach MS. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ Res 2007; 101: 743–745. [DOI] [PubMed] [Google Scholar]
- 13. Everett TH IV, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4: S24–S27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with ventricular dysfunction. Circulation 1999; 100: 376–380. [DOI] [PubMed] [Google Scholar]
- 15. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–2931. [DOI] [PubMed] [Google Scholar]
- 16. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new‐onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–719. [DOI] [PubMed] [Google Scholar]
- 17. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val‐HeFT). Am Heart J 2005; 149: 548–557. [DOI] [PubMed] [Google Scholar]
- 18. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: the CHARM‐Alternative trial. Lancet 2003; 362: 772–776. [DOI] [PubMed] [Google Scholar]
- 19. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186: 1–20. [DOI] [PubMed] [Google Scholar]
- 20. Lombès M, Alfaidy N, Eugene E, et al. Prerequisite for aldosterone action. Mineralocorticoid receptor and 11β‐hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175–182. [DOI] [PubMed] [Google Scholar]
- 21. Konishi A, Tazawa C, Miki Y, et al. The possible of mineralocorticoid receptor and 11β‐hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Steroid Biochem Mol Biol 2003; 85: 439–442. [DOI] [PubMed] [Google Scholar]
- 22. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643–650. [DOI] [PubMed] [Google Scholar]
- 23. Shroff SC, Ryu K, Martovitz NL, et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006; 17: 534–541. [DOI] [PubMed] [Google Scholar]